This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novartis can’t amend complaint, seek US jury trial in generic drug battle with MSN Pharmaceuticals

By Melissa Ritti ( October 28, 2024, 19:16 GMT | Insight) -- Importation in August by India’s MSN Pharmaceuticals of 300,000 bottles of sacubitril/valsartan tablets to US subsidiary Novadoz wasn't enough to convince a US judge to convert litigation over MSN’s recently-approved generic into a case for active infringement. A request by Novartis — maker of the blockbuster cardiovascular drug Entresto — to file an amended complaint adding Novadoz as a defendant and to assert its right to a jury trial was denied. A bench trial against different generic drugmakers but involving the same patent took place in February.Novadoz, a US-based subsidiary of India’s MSN Pharmaceuticals, won't be pulled into protracted patent litigation between MSN Pharmaceuticals and Novartis....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections